Elizabeth Garofalo Sells 1,600 Shares of ACADIA Pharmaceuticals Stock

Elizabeth Garofalo, a director at ACADIA Pharmaceuticals Inc., sold 1,600 shares of the company’s stock on September 2, 2023. The shares were sold at an average price of $25.98, resulting in a total value of $41,568.00.

Following this transaction, Garofalo holds 25,382 shares in ACADIA, with a current value estimated at $659,424.36. This sale marks a 5.93% decrease in her ownership of the company’s stock, as disclosed in a filing with the Securities and Exchange Commission (SEC).

Current Stock Performance and Market Position

As of the latest trading session, ACADIA Pharmaceuticals’ stock opened at $25.50, reflecting a decline of 0.9%. The company has a market capitalization of $4.30 billion, with a price-to-earnings (P/E) ratio of 19.17 and a price-to-earnings-growth (PEG) ratio of 6.52. Additionally, the stock has a beta of 0.75, indicating lower volatility compared to the market.

Over the past year, ACADIA’s stock has seen a range between a low of $13.40 and a high of $26.65. The 50-day simple moving average stands at $23.62, while the 200-day moving average is $20.12.

Recent Financial Results and Analyst Insights

On August 6, 2023, ACADIA Pharmaceuticals released its quarterly earnings, reporting earnings per share (EPS) of $0.16. This figure surpassed analysts’ consensus estimate of $0.14 by $0.02. The company generated revenue of $264.57 million, exceeding expectations of $263.07 million. The firm also demonstrated a return on equity of 14.69% and a net margin of 21.80%, with quarterly revenue increasing by 9.4% year-over-year.

Looking ahead, analysts predict that ACADIA Pharmaceuticals will report an EPS of $0.70 for the current year. A number of research firms have recently adjusted their ratings and price targets for the stock. For instance, Wall Street Zen upgraded ACADIA from a “hold” to a “buy” rating on August 16, 2023. JPMorgan Chase & Co. raised their price target from $30.00 to $34.00 with an “overweight” rating, while Robert W. Baird increased their target from $28.00 to $31.00.

Overall, investment analysts have assigned ACADIA Pharmaceuticals an average rating of “Moderate Buy” with a target price of $28.88 according to MarketBeat.com. One analyst has given the stock a “Strong Buy” rating, with ten others rating it as a “Buy,” six as a “Hold,” and one as a “Sell.”

ACADIA Pharmaceuticals focuses on developing and commercializing innovative medicines aimed at addressing unmet medical needs in central nervous system disorders and rare diseases. The company is known for products like NUPLAZID (pimavanserin), which treats hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, a treatment for Rett Syndrome.

The dynamics surrounding ACADIA’s stock and its recent sales activity highlight the ongoing market response to its financial performance and strategic direction.